Phase I study of ASC 37 in obesity
Latest Information Update: 09 Feb 2026
At a glance
- Drugs ASC 37 (Primary)
- Indications Obesity
- Focus Adverse reactions
Most Recent Events
- 09 Feb 2026 According to the Ascletis media release, company expected initiation of our Phase I study in the second half of 2026 will be another step in our comprehensive strategy to improve the treatment options for people with obesity."
- 09 Feb 2026 New trial record